Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

• Publication year

  2014

• Venue

  Leukemia

• Publication date

  2014-10-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2014.300PMID 25306900PMCID 4318711
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heat shock proteins in multiple myeloma

  2014cited by this paper
• Inhibition of HSP90 molecular chaperones: moving into the clinic.

  2013cited by this paper
• 290 TAS-116, a Novel, Orally Bioavailable Highly Potent HSP90a/β Selective Inhibitor Demonstrates Favorable Tissue Distribution Properties Which Lead to Minimized Ocular Toxicity

  2012cited by this paper
• 291 TAS-116, a Novel, Orally Bioavailable HSP90a/β Selective Inhibitor Demonstrates Highly Potent Antitumor Activity in Preclinical Models with a Favorable PK Profile

  2012cited by this paper
• A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

  2011cited by this paper
• Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma

  2011cited by this paper
• Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells.

  2010cited by this paper
• Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma

  2010cited by this paper
• Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

  2009cited by this paper
• Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

  2009cited by this paper
• Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

  2006cited by this paper
• Antimyeloma activity of heat shock protein-90 inhibition.

  2005cited by this paper
• Heat shock protein 90 as a molecular target for cancer therapeutics.

  2003cited by this paper
• Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.

  2003cited by this paper
• The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

  2001cited by this paper
• Leukemia

  1984cited by this paper

• Overcoming cancer drug resistance through small-molecule targeting of HSP90 and HSP70

  2025cites this paper
• Combination of HSP90 Inhibitors and HSP70 Inducers Prevent Hydrochloric Acid-Induced Pulmonary Fibrosis in Rabbits

  2025cites this paper
• Novel tropane analogues as Hsp90 inhibitors targeting colon cancer: Synthesis, biological estimation, and molecular docking study.

  2024cites this paper
• Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.

  2023cites this paper
• Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins.

  2022cites this paper
• Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances.

  2022cites this paper
• Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

  2022cites this paper
• TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells

  2021influential citation
• Overcoming drug resistance by targeting protein homeostasis in multiple myeloma

  2021cites this paper
• Targeting heat shock protein 90 for anti-cancer drug development.

  2021cites this paper
• Prognosis and predictive value of heat-shock proteins expression in oral cancer

  2021cites this paper
• Combined Detection of Serum Heat Shock Protein-90α and Prostate Specific Antigen for Prostate Cancer Diagnosis

  2020cites this paper
• Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research

  2020cites this paper
• Plasma Heat Shock Protein 90 Alpha: A Valuable Predictor of Early Chemotherapy Effectiveness in Advanced Non-Small-Cell Lung Cancer

  2020cites this paper
• 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents.

  2020cites this paper
• Heat Shock Protein 90 Inhibitors in Lung Cancer Therapy

  2019cites this paper
• Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis

  2019cites this paper
• Fusicoccane Diterpenes from Hypoestes forsskaolii as Heat Shock Protein 90 (Hsp90) Modulators.

  2019cites this paper
• Microarray-based data mining reveals key genes and potential therapeutic drugs for Cadmium-induced prostate cell malignant transformation.

  2019cites this paper
• Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.

  2019cites this paper
• HSP90 Inhibitors Blocking Multiple Oncogenic Signaling Pathways for the Treatment of Cancer

  2019cites this paper
• Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.

  2018cites this paper
• Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach

  2017cites this paper
• Heat Shock Proteins and Cancer.

  2017cites this paper
• Identification of Limonol Derivatives as Heat Shock Protein 90 (Hsp90) Inhibitors through a Multidisciplinary Approach.

  2016cites this paper
• Targeting Hsp90 in Non-Cancerous Maladies.

  2016cites this paper
• TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation

  2016cites this paper
• IRE1α-XBP1 signaling pathway, a potential therapeutic target in multiple myeloma.

  2016cites this paper
• Novel therapeutic strategies for multiple myeloma.

  2015cites this paper
• Acid-labile boronate-bridged dextran-bortezomib conjugate with up-regulated hypoxic tumor suppression.

  2015cites this paper
• Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas

  2015cites this paper
• Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits

  2015cites this paper
• Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

  2015cites this paper